Company profile
Legend Biotech Corporation
LEGN · NASDAQ (Nanjing Legend Biotech Co., Ltd. is the Chinese manufacturing/R&D subsidiary of Legend Biotech Corporation (developer of ciltacabtagene autoleucel/Carvykti with J&J), which trades on NASDAQ under LEGN (majority-owned, ~48%, by GenScript Biotech Corporation). No existing roster row found for Legend Biotech; canonical name set to the public parent rather than the local subsidiary. Sources: financecharts.com, stocktitan.net, SEC EX-21.1 subsidiary list. Sources: https://clinicaltrials.gov/study/NCT03090659 Entity resolved by asset-pipeline-v2.)
Share price · LEGN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Preclinical | FCRL5Cell therapy | Multiple Myeloma |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.